Durvalumab Immediately After Completion of Chemoradiotherapy in Patients With Unresectable Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study)
Clin. Cancer Res 2024 Jan 02;[EPub Ahead of Print], S Nakamichi, K Kubota, T Misumi, T Kondo, S Murakami, Y Shiraishi, H Imai, D Harada, K Isobe, H Itani, S Takata, H Wakui, Y Misumi, S Ikeda, T Asao, N Furuya, S Hosokawa, Y Kobayashi, Y Takiguchi, H OkamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.